Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278939 | 0.82 | ACACB (0.37) | ESRRBMMP8ACACBACACA | |
| SCHEMBL17897630 | 0.81 | CA2 (0.45) | MMP8 | |
| SCHEMBL16811778 | 0.80 | MMP8 (0.35) | MMP8 | |
| SCHEMBL11913584 | 0.80 | MMP8 (0.35) | MMP8 | |
| SCHEMBL12363480 | 0.80 | MMP8 (0.35) | MMP8 | |
| SCHEMBL10156018 | 0.79 | MMP8 (0.39) | ESRRBMMP8 | |
| SCHEMBL10838592 | 0.78 | MMP8 (0.37) | ESRRBMMP8 | |
| SCHEMBL18098452 | 0.78 | MMP8 (0.37) | ESRRBMMP8 | |
| SCHEMBL14668148 | 0.78 | DGAT1 (0.34) | MMP8 | |
| SCHEMBL10349871 | 0.78 | DGAT1 (0.34) | MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346733-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | DIFFUSION PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230346733-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | DIFFUSION PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230301923-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11666538-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666538-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11622941-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2023-04-11 | — | — | US | disclosed |
| US-11357733-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210338591-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES, LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210205226-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | Triastek, Inc. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-20210128480-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES, LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20160287523-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-10-06 | — | — | US | disclosed |
| US-20160287523-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-10-06 | — | — | US | disclosed |
| US-20160250170-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-09-01 | — | — | US | disclosed |
| US-20160250170-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-09-01 | — | — | US | disclosed |
| US-20150352068-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | DIFFUSION PHARMACEUTICALS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150352068-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | DIFFUSION PHARMACEUTICALS LLC | 2015-12-10 | — | — | US | disclosed |
| US-8974822-B2 | Oral formulations of bipolar trans carotenoids | DIFFUSION PHARMACEUTICALS LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-8974822-B2 | Oral formulations of bipolar trans carotenoids | DIFFUSION PHARMACEUTICALS LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20110300213-A1 | Oral formulations of bipolar trans carotenoids | DIFFUSION PHARMACEUTICALS LLC | 2011-12-08 | — | — | US | disclosed |
| US-20110300213-A1 | Oral formulations of bipolar trans carotenoids | DIFFUSION PHARMACEUTICALS LLC | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300213-A1 | Oral formulations of bipolar trans carotenoids | CRY1, CYP11B1, BBC3 | ESRRB 2754/4885MMP8 4249/4885ACACB 1497/4885 |
| US-20230346733-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | CRY1, CYP11B1, BBC3 | ESRRB 2754/4885MMP8 4249/4885ACACB 1497/4885 |
| US-20150352068-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | CRY1, CYP11B1, BBC3 | ESRRB 2754/4885MMP8 4249/4885ACACB 1497/4885 |
| US-11666538-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | COMT, MUC1, MLNR | ESRRB 3900/4885MMP8 3922/4885ACACB 2811/4885 |
| US-20160287523-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, DDO, SLC6A3 | ESRRB 4023/4885MMP8 3664/4885ACACB 1414/4885 |
| US-20160250170-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, DDO, DAO | ESRRB 3997/4885MMP8 3668/4885ACACB 1344/4885 |
| US-11622941-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | COMT, MUC1, MLNR | ESRRB 3900/4885MMP8 3922/4885ACACB 2811/4885 |
| US-20230301923-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, MLNR, MUC1 | ESRRB 3631/4885MMP8 4423/4885ACACB 2562/4885 |
| US-20210128480-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, DDO, SLC6A3 | ESRRB 4023/4885MMP8 3664/4885ACACB 1414/4885 |
| US-20210338591-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, MUC1, MLNR | ESRRB 3900/4885MMP8 3922/4885ACACB 2811/4885 |
| US-11357733-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | COMT, DDO, SLC6A3 | ESRRB 4023/4885MMP8 3664/4885ACACB 1414/4885 |
| US-20210205226-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | CYP2D6, CYP3A5, CYP3A7 | ESRRB 4056/4885MMP8 4227/4885ACACB 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.